Objective: To evaluate the clinical efficacy of neoadjuvant chemotherapy combined with trastuzumab for HER-2 positive breast cancer. Methods: Thirty-nine patients with HER-2 positive breast cancer were treated with six cycles of docetaxel plus carboplatin based neoadjuvant chemotherapy combined with trastuzumab, and then the overall clinical efficacy was observed and univariate analysis was performed between the estrogen receptor (ER) expression status of the cancer tissues and pathologic complete response (pCR) rate. Results: The overall response (OR) rate of the 39 patients was 94.9% (37/39). Of the patients, clinical complete response (cCR) was achieved in 26 cases, partial response (PR) in 11 cases, stable disease in 2 cases and no case of progressive disease (PD). The pCR was seen in 27 cases (69.2%). The univariate analysis showed that the pCR rate of the ER-negative and ER-positive patients was 82.4% and 59.1% respectively. Conclusion: The docetaxel plus carboplatin based neoadjuvant chemotherapy combined with trastuzumab has demonstrable efficacy for HER-2 positive breast cancer, and the ER-negative patients can obtain a higher response rate.